Manali Bhave
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (1)
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples ( n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
Year:
2024
Collaborators (9)
Patrick Neven
University Hospitals Leuven
Francois-Clement Bidard
Professor of Medical Oncology
Institut Curie
Nadia Harbeck
-
Kelly K Hunt
Chair
The University of Texas MD Anderson Cancer Center
Peter Schmid
Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute
Peter Fasching
-
Swati Kulkarni
Professor of Surgery
Northwestern University
Miguel Martin
Universidad Complutense de Madrid
Eva M. Ciruelos-Gil
Universidad Complutense de Madrid
Make your next move.
Prepare your application
Review drafts before you send them.